

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED**

**大成生化科技集團有限公司 \***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 00809)**

### **PROFIT WARNING**

This announcement is made by Global Bio-chem Technology Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that based on the preliminary review of the Group’s unaudited consolidated management accounts for the year ended 31 December 2022 (the “**Year**”) currently available to the Group, the revenue and gross profit of the Group for the Year have decreased by approximately 50.1% and 28.5% to approximately HK\$372.3 million and HK\$34.6 million, respectively, as compared with the revenue of HK\$746.6 million and gross profit of HK\$48.4 million recorded for the year ended 31 December 2021. The net loss of the Group for the Year has also increased significantly by over 200% as compared with the net loss of approximately HK\$435.4 million recorded for the year ended 31 December 2021. The significant increase in net loss was mainly attributable to: (i) the absence of a one-off gain on debt restructuring (amounted to approximately HK\$1,325.0 million recorded for the year ended 31 December 2021 as a result of the completion of the Group Repurchase Agreements and Other Repurchase Agreements, as defined and previously disclosed in the joint announcements of the Company and Global Sweeteners Holdings Limited dated 26 March 2021 and 31 March 2021) during the Year which led to a significant drop in other income of the Group for the Year as compared with the year ended 31 December 2021; and (ii) the decrease in production volume of the Group due to temporary suspension of production operation of the Group’s production facilities in Shanghai, the People’s Republic of China, during the second quarter of the Year (the “**Temporary Suspension**”) pursuant to the lock down measures implemented in Shanghai in response to the outbreak of the COVID-19 epidemic as announced by the Company on 14 April 2022.

Despite the drops in the Group's revenue and gross profit as a result of the drop in sales volume due to the Temporary Suspension, the gross profit margin of Group has actually improved by approximately 2.8% to 9.3% during the Year as compared to the gross profit margin of 6.5% recorded for the year ended 31 December 2021. Such increase was a result of the improvement in corn sweetener prices and the stringent cost control measures of the Group during the Year.

The information contained in this announcement is only based on the preliminary assessment by the management of the Group with reference to the unaudited consolidated management accounts of the Group for the Year which have not been reviewed or audited by the Company's auditor. Shareholders of the Company and the potential investors are advised to read carefully the final results announcement of the Company for the Year which is expected to be published by the end of March 2023.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Global Bio-chem Technology Group Company Limited**  
**Yang Jian**  
*Chairman*

Hong Kong, 16 February 2023

*As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Yang Jian and Mr. Wang Guicheng; one non-executive Director, namely, Mr. Gao Dongsheng; and three independent non-executive Directors, namely, Ms. Dong Hongxia, Mr. Ng Kwok Pong and Mr. Yeung Kit Lam.*

*\*For identification purposes only*